Galapagos And Gilead Collaborate On Ouro's $1.675B Acquisition, Retaining $500M Cash With Up To $150M Return To Shareholders

Galapagos has entered into a collaboration with Gilead for the acquisition of Ouro for $1.675 billion, while retaining $500 million in cash. This new structure enhances financial terms and flexibility for Galapagos, allowing for further strategic transactions and capital allocation. The collaboration also presents an opportunity to develop a potential first-in-class T cell engager for autoimmune diseases.